Emerging Therapeutic Delivery Capabilities and Challenges Utilizing Enzyme/Protein Packaged Bacterial Vesicles

References

• Lee N Choi SH Hyeon T . Nano-sized CT contrast agents. Adv. Mater.25 (19), 2641–2660 (2013).
   PubMed Web of Science ®Google Scholar
• Rahman M Ahmad MZ Kazmi I et al. Emergence of nanomedicine as cancer targeted magic bullets: recent development and need to address the toxicity apprehension. Curr. Drug Discov. Technol.9 (4), 319–329 (2012).
   PubMedGoogle Scholar
• Shin MC Zhang J Min KA et al. Cell-penetrating peptides: achievements and challenges in application for cancer treatment. J. Biomed. Mater. Res. A.102 (2), 575–587 (2014).
   PubMed Web of Science ®Google Scholar
• van Riet E Ainai A Suzuki T Kersten G Hasegawa H . Combatting infectious diseases; nanotechnology as a platform for rational vaccine design. Adv. Drug Deliver. Rev.74, 28–34 (2014).
   PubMed Web of Science ®Google Scholar
• Bertrand N Wu J Xu X Kamaly N Farokhzad OC . Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliver. Rev.66, 2–25 (2014).
   PubMed Web of Science ®Google Scholar
• Guo S Huang L . Nanoparticles containing insoluble drug for cancer therapy. Biotechnol. Adv.32 (4), 778–788 (2014).
   PubMed Web of Science ®Google Scholar
• Highsmith J . Nanoparticles In Biotechnology, Drug Development And Drug Delivery. BCC Research, MA, USA, 187 (2012).
   Google Scholar
• Lopez-Abarrategui C Figueroa-Espi V Reyes-Acosta O Reguera E Otero-Gonzalez AJ . Magnetic nanoparticles: new players in antimicrobial peptide therapeutics. Curr. Protein Pept. Sci.14 (7), 595–606 (2013).
   PubMed Web of Science ®Google Scholar
• Hassan S Singh AV . Biophysicochemical perspective of nanoparticle compatibility: a critically ignored parameter in nanomedicine. J. Nanosci. Nanotechnol.14 (1), 402–414 (2014).
   PubMed Web of Science ®Google Scholar
• Tu Q Zhang Y Liu R et al. Active drug targeting of disease by nanoparticles functionalized with ligand to folate receptor. Curr. Med. Chem.19 (19), 3152–3162 (2012).
   PubMed Web of Science ®Google Scholar
• Steichen SD Caldorera-Moore M Peppas NA . A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci.48 (3), 416–427 (2013).
   PubMed Web of Science ®Google Scholar
• Johnson BJ Algar WR Malanoski AP Ancona MG Medintz IL . Understanding enzymatic acceleration at nanoparticle interfaces: approaches and challenges. Nano Today9 (1), 102–131 (2014).
   Web of Science ®Google Scholar
• Natarajan JV Nugraha C Ng XW Venkatraman S . Sustained-release from nanocarriers: a review. J. Control. Release193, 122–138 (2014).
   PubMed Web of Science ®Google Scholar
• Spillmann CM Naciri J Algar WR Medintz IL Delehanty JB . Multifunctional liquid crystal nanoparticles for intracellular fluorescent imaging and drug delivery. ACS Nano8 (7), 6986–6997 (2014).
   PubMed Web of Science ®Google Scholar
• Barar J Omidi Y . Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. BioImpacts4 (1), 3–14 (2014).
   PubMedGoogle Scholar
• Duan X Li Y . Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small9 (9–10), 1521–1532 (2013).
   PubMed Web of Science ®Google Scholar
• Dellinger A Zhou Z Connor J et al. Application of fullerenes in nanomedicine: an update. Nanomedicine (Lond.)8 (7), 1191–1208 (2013).
   PubMed Web of Science ®Google Scholar
• Guo R Shi X . Dendrimers in cancer therapeutics and diagnosis. Curr. Drug Metab.13 (8), 1097–1109 (2012).
   PubMed Web of Science ®Google Scholar
• Bharali DJ Khalil M Gurbuz M Simone TM Mousa SA . Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int. J. Nanomed.4 (1), 1–7 (2009).
   PubMed Web of Science ®Google Scholar
• Madaan K Kumar S Poonia N Lather V Pandita D . Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J. Pharm. Bioallied Sci.6 (3), 139–150 (2014).
   PubMedGoogle Scholar
• Duncan R Vicent MJ . Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv. Drug Deliver. Rev.65 (1), 60–70 (2013).
   PubMed Web of Science ®Google Scholar
• Ginn C Khalili H Lever R Brocchini S . Pegylation and its impact on the design of new protein-based medicines. Future Med. Chem.6 (16), 1829–1846 (2014).
   PubMed Web of Science ®Google Scholar
• Paraskar AS Soni S Chin KT et al. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc. Natl Acad. Sci. USA107 (28), 12435–12440 (2010).
   PubMed Web of Science ®Google Scholar
• Gokmen MT Du Prez FE . Porous polymer particles–a comprehensive guide to synthesis, characterization, functionalization and applications. Prog. Polym. Sci.37 (3), 365–405 (2012).
   Web of Science ®Google Scholar
• Nazemi K Azadpour P Moztarzadeh F Urbanska AM Mozafari M . Tissue-engineered chitosan/bioactive glass bone scaffolds integrated with plga nanoparticles: a therapeutic design for on-demand drug delivery. Mater. Lett.138, 16–20 (2015).
   Web of Science ®Google Scholar
• Yang Y Wang S Wang Y Wang X Wang Q Chen M . Advances in self-assembled chitosan nanomaterials for drug delivery. Biotechnol. Adv.32 (7), 1301–1316 (2014).
   PubMed Web of Science ®Google Scholar
• Gentile P Chiono V Carmagnola I Hatton PV . An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int. J. Mol. Sci.15 (3), 3640–3659 (2014).
   PubMed Web of Science ®Google Scholar
• Mirakabad FST Nejati-Koshki K Akbarzadeh A et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac. J. Cancer Prev.15 (2), 517–535 (2014).
   PubMedGoogle Scholar
• Ikeda Y Nagasaki Y . Pegylation technology in nanomedicine. In : Polymers In Nanomedicine (Volume 247). KunugiSYamaokaT ( Eds). Springer Berlin Heidelberg, Berlin, Germany, 115–140 (2012).
   Google Scholar
• Acharya A . Luminescent magnetic quantum dots for in vitro/in vivo imaging and applications in therapeutics. J. Nanosci. Nanotechnol.13 (6), 3753–3768 (2013).
   PubMed Web of Science ®Google Scholar
• Mok H Zhang M . Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics. Expert Opin. Drug Del.10 (1), 73–87 (2013).
   PubMed Web of Science ®Google Scholar
• Singh D McMillan JM Liu X-M et al. Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine (Lond.)9 (3), 469–485 (2014).
   PubMed Web of Science ®Google Scholar
• Zheng S-G Xu H-X Chen H-R . Nano/microparticles and ultrasound contrast agents. World J. Radiol.5 (12), 468–471 (2013).
   PubMedGoogle Scholar
• Cormode DP Skajaa GO Delshad A et al. A versatile and tunable coating strategy allows control of nanocrystal delivery to cell types in the liver. Bioconjugate Chem.22 (3), 353–361 (2011).
   PubMed Web of Science ®Google Scholar
• Nam J Won N Bang J et al. Surface engineering of inorganic nanoparticles for imaging and therapy. Adv. Drug Deliver. Rev.65 (5), 622–648 (2013).
   PubMed Web of Science ®Google Scholar
• Sengupta J Ghosh S Datta P Gomes A Gomes A . Physiologically important metal nanoparticles and their toxicity. J. Nanosci. Nanotechnol.14 (1), 990–1006 (2014).
   PubMed Web of Science ®Google Scholar
• Simpson CA Salleng KJ Cliffel DE Feldheim DL . In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. Nanomed. Nanotechnol.9 (2), 257–263 (2013).
   PubMed Web of Science ®Google Scholar
• Torchilin VP . Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov.4 (2), 145–160 (2005).
   PubMed Web of Science ®Google Scholar
• Dawidczyk CM Kim C Park JH et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control. Release187, 133–144 (2014).
   PubMed Web of Science ®Google Scholar
• Ang CY Tan SY Zhao Y . Recent advances in biocompatible nanocarriers for delivery of chemotherapeutic cargoes towards cancer therapy. Org. Biomol. Chem.12 (27), 4776–4806 (2014).
   PubMed Web of Science ®Google Scholar
• Anselmo AC Mitragotri S . An overview of clinical and commercial impact of drug delivery systems. J. Control. Release190, 15–28 (2014).
   PubMed Web of Science ®Google Scholar
• Cooper DL Conder CM Harirforoosh S . Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity. Expert Opin. Drug Del.11 (10), 1661–1680 (2014).
   PubMed Web of Science ®Google Scholar
• Kraft JC Freeling JP Wang Z Ho RJY . Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J. Pharm. Sci.103 (1), 29–52 (2014).
   PubMed Web of Science ®Google Scholar
• Chen WC May JP Li S-D . Immune responses of therapeutic lipid nanoparticles. Nanotechnol. Rev.2 (2), 201–213 (2013).
   Web of Science ®Google Scholar
• Allen TM . Long-circulating (sterically stabilized) liposomes for targeted drug-delivery. Trends Pharmacol. Sci.15 (7), 215–220 (1994).
   PubMed Web of Science ®Google Scholar
• Marques-Gallego P de Kroon AIPM . Ligation strategies for targeting liposomal nanocarriers. Biomed Res. Int.2014, 1–12 (2014).
   Web of Science ®Google Scholar
• Barenholz Y . Liposome application: problems and prospects. Curr. Opin. Colloid In.6 (1), 66–77 (2001).
   Web of Science ®Google Scholar
• Kiziltepe T Ashley JD Stefanick JF et al. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J.2 (4), e64 (2012).
   PubMedGoogle Scholar
• Ashley JD Stefanick JF Schroeder VA et al. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. J. Control. Release196, 113–121 (2014).
   PubMed Web of Science ®Google Scholar
• Beveridge TJ . Structures of gram-negative cell walls and their derived membrane vesicles. J. Bacteriol.181 (16), 4725–4733 (1999).
   PubMed Web of Science ®Google Scholar
• Kulkarni HM Jagannadham MV . Biogenesis and multifaceted roles of outer membrane vesicles from gram-negative bacteria. Microbiology160 (Pt 10), 2109–2121 (2014).
   PubMed Web of Science ®Google Scholar
• Kulp A Kuehn MJ . Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu. Rev. Microbiol.64 (1), 163–184 (2010).
   PubMed Web of Science ®Google Scholar
• Remis JP Wei D Gorur A et al. Bacterial social networks: structure and composition ofmyxococcus xanthusouter membrane vesicle chains. Environ. Microbiol.16 (2), 598–610 (2014).
   PubMed Web of Science ®Google Scholar
• Yaron S Kolling GL Simon L Matthews KR . Vesicle-mediated transfer of virulence genes from escherichia coli O157:H7 to other enteric bacteria. Appl. Environ. Microb.66 (10), 4414–4420 (2000).
   PubMed Web of Science ®Google Scholar
• Mashburn-Warren L Howe J Garidel P et al. Interaction of quorum signals with outer membrane lipids: insights into prokaryotic membrane vesicle formation. Mol. Microbiol.69 (2), 491–502 (2008).
   PubMed Web of Science ®Google Scholar
• Kato S Kowashi Y Demuth DR . Outer membrane-like vesicles secreted by actinobacillus actinomycetemcomitans are enriched in leukotoxin. Microb. Pathogenesis32 (1), 1–13 (2002).
   PubMed Web of Science ®Google Scholar
• Horstman AL . Enterotoxigenic escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles. J. Biol. Chem.275 (17), 12489–12496 (2000).
   PubMed Web of Science ®Google Scholar
• Park AJ Surette MD Khursigara CM . Antimicrobial targets localize to the extracellular vesicle-associated proteome of pseudomonas aeruginosa grown in a biofilm. Front. Microbiol.5, 464 (2014).
   PubMed Web of Science ®Google Scholar
• Lee E-Y Choi D-S Kim K-P Gho YS . Proteomics in gram-negative bacterial outer membrane vesicles. Mass Spectrom. Rev.27 (6), 535–555 (2008).
   PubMed Web of Science ®Google Scholar
• Lee E-Y Bang JY Park GW et al. Global proteomic profiling of native outer membrane vesicles derived from escherichia coli. Proteomics7 (17), 3143–3153 (2007).
   PubMed Web of Science ®Google Scholar
• Haurat MF Aduse-Opoku J Rangarajan M et al. Selective sorting of cargo proteins into bacterial membrane vesicles. J. Biol. Chem.286 (2), 1269–1276 (2011).
   PubMed Web of Science ®Google Scholar
• Simpson D McCormack PL Keating GM Lyseng-Williamson KA . Insulin lispro–a review of its use in the management of diabetes mellitus. Drugs67 (3), 407–434 (2007).
   PubMed Web of Science ®Google Scholar
• Kesty NC Kuehn MJ . Incorporation of heterologous outer membrane and periplasmic proteins into escherichia coli outer membrane vesicles. J. Biol. Chem.279 (3), 2069–2076 (2003).
   PubMed Web of Science ®Google Scholar
• Gujrati V Kim S Kim S-H et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano8 (2), 1525–1537 (2014).
   PubMed Web of Science ®Google Scholar
• Ghrayeb J Inouye M . Nine amino acid residues at the NH2-terminal of lipoprotein are sufficient for its modification, processing, and localization in the outer-membrane of Escherichia coli. J. Biol. Chem.259 (1), 463–467 (1984).
   PubMed Web of Science ®Google Scholar
• Francisco JA Campbell R Iverson BL Georgiou G . Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc. Natl Acad. Sci. USA90 (22), 10444–10448 (1993).
   PubMed Web of Science ®Google Scholar
• Sapsford KE Algar WR Berti L et al. Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. Chem. Rev.113 (3), 1904–2074 (2013).
   PubMed Web of Science ®Google Scholar
• Algar WR Prasuhn DE Stewart MH et al. The controlled display of biomolecules on nanoparticles: a challenge suited to bioorthogonal chemistry. Bioconjug. Chem.22 (5), 825–858 (2011).
   PubMed Web of Science ®Google Scholar
• Alves NJ Cusick W Stefanick JF Ashley JD Handlogten MW Bilgicer B . Functionalized liposome purification via liposome extruder purification (LEP). Analyst138 (17), 4746–4751 (2013).
   PubMed Web of Science ®Google Scholar
• Steeghs L Kuipers B Hamstra HJ Kersten G van Alphen L van der Ley P . Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of neisseria meningitidis: influence of adjuvants on the immune response. Infect. Immun.67 (10), 4988–4993 (1999).
   PubMed Web of Science ®Google Scholar
• Sapsford KE Tyner KM Dair BJ Deschamps JR Medintz IL . Analyzing nanomaterial bioconjugates: a review of current and emerging purification and characterization techniques. Anal. Chem.83 (12), 4453–4488 (2011).
   PubMed Web of Science ®Google Scholar
• Patterson DP Prevelige PE Douglas T . Nanoreactors by programmed enzyme encapsulation inside the capsid of the bacteriophage P22. ACS Nano6 (6), 5000–5009 (2014).
   Web of Science ®Google Scholar
• Jang SC Kim SR Yoon YJ et al. In vivo kinetic biodistribution of nano-sized outer membrane vesicles derived from bacteria. Small11 (4), 456–461 (2015).
   PubMed Web of Science ®Google Scholar